Abstract 4328
Background
The treatment of cancer has improved and many of the patients’ will return to work. Cancer treatments can have significant impact on work- and functional abilities creating challenges for return to work. Occupational health care services have an important role in supporting patients’ Return-to-Work-process. The purpose of the study was to a) explore cancer patients experiences on support received from occupational health services and b) explore how the services need to be developed.
Methods
Qualitative approach with thematic interview as data collection method was used to explore breast cancer patientś experiences (N = 8). The data was analysed by using thematic content analysis. Five of the cancer patients interviewed had already returned to work after cancer treatments and three were returning work in short period of time.
Results
The main challenges cancer patients confronted formed four categories; factors related to work, workplace, cancer and treatment types and to individual factors. The experienced support by occupational health services varied. The requirement to assess ability to work in the time of 90 sickness days was filled and planning the return-to-work in collaboration between occupational health care, cancer patient and employer occurred in most cases. However, otherwise, the role was passive and patients wished to have more contact with professionals working in the occupational health services.
Conclusions
Previous research highlights the need of collaboration between cancer patients and occupational health care services. Based on the study results, this collaboration needs to be enhanced. Occupational health care providers need to co-ordinate more actively the return-to-work -processes even the special health care is responsible for cancer treatments. From individual perspective, information, psychosocial support and regular evaluation of ability to work are forms of services cancer patient need from the occupational services for successful Return-to-Work. Results of this study can be used to developing occupational health services in national and international context.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Turku University of Applied Sciences.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5368 - Durvalumab and Paclitaxel Combination for treatment of metastatic triple negative breast cancer is safe with very promising efficacy
Presenter: Hazem Ghebeh
Session: Poster Display session 3
Resources:
Abstract
1520 - A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients
Presenter: Daan Hurkmans
Session: Poster Display session 3
Resources:
Abstract
1603 - Safety and clinical activity of subcutaneously (SC) administered anti-PD-1 antibody PF-06801591 in phase I dose-expansion cohorts of locally advanced or metastatic non-small-cell lung cancer (NSCLC) and urothelial carcinoma (UC)
Presenter: Byoung Cho
Session: Poster Display session 3
Resources:
Abstract
3922 - Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A scale to measure quality of life in cancer patients treated with ICMs
Presenter: Aaron Hansen
Session: Poster Display session 3
Resources:
Abstract
2408 - Immune checkpoint inhibitors (ICIs) as “chemotherapy (Ctx) sensitization” strategy in advanced solid tumors
Presenter: Francisco Javier Ros Montana
Session: Poster Display session 3
Resources:
Abstract
3612 - Validation of progression-free survival (PFS) as surrogate endpoint in randomised trials of immune checkpoint inhibitors in advanced solid cancers
Presenter: Peey Sei Kok
Session: Poster Display session 3
Resources:
Abstract
3827 - Pharmacokinetic (PK) analysis of weight-based and fixed dose cemiplimab in patients (pts) with advanced malignancies
Presenter: Michael Migden
Session: Poster Display session 3
Resources:
Abstract
2120 - A burst of highly differentiated CD4 TL identifies a subset of fast progressors, and correlates with hyperprogressive disease in NSCLC patients treated with ICI
Presenter: Hugo Arasanz
Session: Poster Display session 3
Resources:
Abstract
4254 - Nivolumab treatment in advanced non-small cell lung cancer (aNSCLC): a French nationwide retrospective cohort (UNIVOC Study)
Presenter: Christos Chouaid
Session: Poster Display session 3
Resources:
Abstract
1084 - Dissociated responses in patients with metastatic solid tumors treated with immunotherapy
Presenter: Pauline Vaflard
Session: Poster Display session 3
Resources:
Abstract